|
|
|
| 【主 题】 ： |
Tasimelteon |
| 【联系人名】 ： |
Linna Green |
| 【电子邮件】 ： |
account@bocsci.com |
| 【联系电话】 ： |
15166698109 |
| 【发布日期】 ： |
2016-8-26 |
| 【详细说明】 ： |
Tasimelteon (trade name Hetlioz) is a drug approved
by the FDA solely for the treatment of non-24-hour
sleep–wake disorder (often designated as N24HSWD)
in totally blind adults. It is a selective agonist
for the melatonin receptors MT1 and MT2 in the
suprachiasmatic nucleus of the brain, similar to
other members of the melatonin receptor agonist
class of which ramelteon (2005) and agomelatine
(2009) were the first approved.
http://www.bocsci.com/tasimelteon-cas-609799-22-6-
item-84-72984.html
|
|
|
|
|
English
